Skip to main content
Peptides TT home

Glossary term

Peptide Purity

Peptide purity is the percentage of a sample that is the intended peptide sequence relative to related impurities, normally measured as HPLC area percent at 214 or 220 nm.

Also known as: HPLC purity, Chromatographic purity

In peptide supply, purity almost always means chromatographic purity: the proportion of UV-absorbing material in a sample that is the intended sequence. It is measured by reversed-phase HPLC and reported as area percent, so a batch quoted at 98% shows a main peak that accounts for 98% of the total integrated peak area.

What the impurities are

Solid-phase peptide synthesis builds a chain one residue at a time, and no coupling step is perfectly efficient. Typical impurities include:

  • Deletion sequences, missing one or more residues.
  • Truncated sequences, where chain growth stopped early.
  • Incompletely deprotected species, still carrying a side-chain protecting group.
  • Oxidised or deamidated forms, for example methionine sulfoxide or aspartimide-related products.

Purification removes most of these, but closely related species can elute very near the main peak, which is why purity specifications are usually expressed as a minimum, such as ≥95% or ≥98%.

Purity is not peptide content

A common point of confusion is the difference between purity and net peptide content. Purity compares the target peptide with other peptide-like impurities. Net peptide content compares the peptide with everything in the vial, including counter-ions and residual water, which are invisible at 214 nm. A batch can therefore be 98% pure by HPLC yet contain, say, 75–85% peptide by mass. Our TFA salt entry explains the counter-ion part of that gap.

Why it matters in the lab

The purity a project needs depends on the method. Sensitive receptor-binding or structural studies generally call for higher-purity material, while some screening work can accept a lower grade. Short sequences such as GRGDS are usually straightforward to purify to a high standard; long, hydrophobic sequences such as Amyloid Beta 1-42 are more demanding.

The purity figure for each batch is printed on its certificate of analysis together with the chromatogram. Our Quality & Testing page describes how batches are checked, and the article on peptide purity testing by HPLC and MS covers the methods in more depth.

Research peptides where Peptide Purity matters

  • Sealed glass vial of lyophilized Tirzepatide research peptide, 30 mg, on a navy background

    CAS 2023788-19-2

    In stock

    Tirzepatide

    Dual GIP/GLP-1 receptor agonist peptide studied in metabolic research, supplied as a 30 mg lyophilized vial for in-vitro and analytical work.

    Purity
    Per batch COA
    Vial
    30 mg

    TT$2,000.00indicative

  • Sealed glass vial of lyophilized Retatrutide research peptide, 20 mg, on a navy background

    CAS 2381089-83-2

    In stock

    Retatrutide

    Investigational GIP, GLP-1 and glucagon triple receptor agonist peptide, supplied as a 20 mg lyophilized vial for in-vitro metabolic research.

    Purity
    Per batch COA
    Vial
    20 mg

    TT$2,200.00indicative

  • Sealed glass vial of lyophilized Tesamorelin research peptide, 10 mg, on a navy background

    CAS 218949-48-5

    In stock

    Tesamorelin

    Synthetic GHRH analogue: the 44-residue human GHRH sequence with an N-terminal trans-3-hexenoyl group, supplied as a 10 mg lyophilized vial.

    Purity
    Per batch COA
    Vial
    10 mg

    TT$1,200.00indicative

  • Sealed glass vial of lyophilized Wolverine Blend, a BPC-157 and TB-500 research peptide blend, on a navy background

    CAS 137525-51-0 / 885340-08-9

    In stock

    Wolverine Blend

    20 mg lyophilized research blend of BPC-157 (10 mg) and TB-500 (10 mg, N-acetyl thymosin β4 17-23), two peptides studied in tissue-repair research models.

    Purity
    Per batch COA
    Vial
    20 mg (10 mg BPC-157 + 10 mg TB-500)

    TT$1,300.00indicative